160 related articles for article (PubMed ID: 29048639)
1. Phenotype characterization of human melanoma cells resistant to dabrafenib.
Cordaro FG; De Presbiteris AL; Camerlingo R; Mozzillo N; Pirozzi G; Cavalcanti E; Manca A; Palmieri G; Cossu A; Ciliberto G; Ascierto PA; Travali S; Patriarca EJ; Caputo E
Oncol Rep; 2017 Nov; 38(5):2741-2751. PubMed ID: 29048639
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
[TBL] [Abstract][Full Text] [Related]
4. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
[TBL] [Abstract][Full Text] [Related]
5. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F
Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892
[TBL] [Abstract][Full Text] [Related]
6. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
7. Helicobacter pylori-induced epithelial-mesenchymal transition, a potential role of gastric cancer initiation and an emergence of stem cells.
Choi YJ; Kim N; Chang H; Lee HS; Park SM; Park JH; Shin CM; Kim JM; Kim JS; Lee DH; Jung HC
Carcinogenesis; 2015 May; 36(5):553-63. PubMed ID: 25784376
[TBL] [Abstract][Full Text] [Related]
8. Onconase Restores Cytotoxicity in Dabrafenib-Resistant A375 Human Melanoma Cells and Affects Cell Migration, Invasion and Colony Formation Capability.
Raineri A; Fasoli S; Campagnari R; Gotte G; Menegazzi M
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31783660
[TBL] [Abstract][Full Text] [Related]
9. [Dabrafenib: the new inhibitor of hyperactive B-RAF kinase].
Heneberg P
Klin Onkol; 2012; 25(5):333-9. PubMed ID: 23102194
[TBL] [Abstract][Full Text] [Related]
10. LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1.
Wang B; Chen Q; Cao Y; Ma X; Yin C; Jia Y; Zang A; Fan W
PLoS One; 2016; 11(12):e0168904. PubMed ID: 28033430
[TBL] [Abstract][Full Text] [Related]
11. Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.
Pal HC; Diamond AC; Strickland LR; Kappes JC; Katiyar SK; Elmets CA; Athar M; Afaq F
Oncotarget; 2016 Jan; 7(2):1227-41. PubMed ID: 26517521
[TBL] [Abstract][Full Text] [Related]
12. SNAIL induces epithelial-to-mesenchymal transition and cancer stem cell-like properties in aldehyde dehydroghenase-negative thyroid cancer cells.
Yasui K; Shimamura M; Mitsutake N; Nagayama Y
Thyroid; 2013 Aug; 23(8):989-96. PubMed ID: 23432420
[TBL] [Abstract][Full Text] [Related]
13. FMNL2 enhances invasion of colorectal carcinoma by inducing epithelial-mesenchymal transition.
Li Y; Zhu X; Zeng Y; Wang J; Zhang X; Ding YQ; Liang L
Mol Cancer Res; 2010 Dec; 8(12):1579-90. PubMed ID: 21071512
[TBL] [Abstract][Full Text] [Related]
14. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT).
Kasai H; Allen JT; Mason RM; Kamimura T; Zhang Z
Respir Res; 2005 Jun; 6(1):56. PubMed ID: 15946381
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase-9 cooperates with transcription factor Snail to induce epithelial-mesenchymal transition.
Lin CY; Tsai PH; Kandaswami CC; Lee PP; Huang CJ; Hwang JJ; Lee MT
Cancer Sci; 2011 Apr; 102(4):815-27. PubMed ID: 21219539
[TBL] [Abstract][Full Text] [Related]
16. BRAF and epithelial-mesenchymal transition in primary cutaneous melanoma: a role for Snail and E-cadherin?
Mitchell B; Leone DA; Feller JK; Yang S; Mahalingam M
Hum Pathol; 2016 Jun; 52():19-27. PubMed ID: 26980024
[TBL] [Abstract][Full Text] [Related]
17. The Crosstalk between Nrf2 and TGF-β1 in the Epithelial-Mesenchymal Transition of Pancreatic Duct Epithelial Cells.
Arfmann-Knübel S; Struck B; Genrich G; Helm O; Sipos B; Sebens S; Schäfer H
PLoS One; 2015; 10(7):e0132978. PubMed ID: 26226105
[TBL] [Abstract][Full Text] [Related]
18. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells.
Kim MR; Choi HK; Cho KB; Kim HS; Kang KW
Cancer Sci; 2009 Oct; 100(10):1834-41. PubMed ID: 19681904
[TBL] [Abstract][Full Text] [Related]
19. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells.
Ji M; Lee EJ; Kim KB; Kim Y; Sung R; Lee SJ; Kim DS; Park SM
Oncol Rep; 2015 May; 33(5):2299-308. PubMed ID: 25813246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
